Table 1.
Baseline characteristics by initial vaccine schedules and sub-study groups in participants who were randomly assigned
|
Two doses of ChAdOx1 nCov-19 plus one dose of BNT162b2 |
Three doses of BNT162b2 |
|||
|---|---|---|---|---|
| Full BNT162b2 as fourth dose (n=44) | Half mRNA-1273 as fourth dose (n=44) | Full BNT162b2 as fourth dose (n=39) | Half mRNA-1273 as fourth dose (n=39) | |
| Age | ||||
| Median, years | 71·2 (52·3–77·4) | 71·6 (52·3–77·2) | 67·2 (52·9–77·9) | 73·2 (52·4–80·5) |
| <70 years | 21 (48%) | 21 (48%) | 20 (51%) | 18 (46%) |
| ≥70 years | 23 (52%) | 23 (52%) | 19 (49%) | 21 (54%) |
| Intervals between doses, days | ||||
| Between first and second | 71·0 (65·0–77·0) | 75·5 (67·5–78·0) | 69·0 (60·5–76·0) | 55·0 (25·5–74·5) |
| Between second and third | 78·0 (73·8–84·2) | 76·5 (73·0–85·0) | 96·0 (90·0–110·5) | 106·0 (90·5–152·5) |
| Between third and fourth | 204·0 (203·0–210·0) | 206·0 (204·0–212·2) | 208·0 (203·5–214·0) | 215·0 (206·5–218·0) |
| Sex | ||||
| Female | 20 (45%) | 22 (50%) | 22 (56%) | 22 (56%) |
| Male | 24 (55%) | 22 (50%) | 17 (44%) | 17 (44%) |
| Occupation | ||||
| Health worker | 13 (30%) | 11 (25%) | 18 (46%) | 17 (44%) |
| Other | 31 (70%) | 33 (75%) | 21 (54%) | 22 (56%) |
| Diabetes | ||||
| Yes | 3 (7%) | 4 (9%) | 2 (5%) | 3 (8%) |
| No | 41 (93%) | 40 (91%) | 37 (95%) | 36 (92%) |
| Respiratory disease | ||||
| Yes | 2 (5%) | 6 (14%) | 2 (5%) | 3 (8%) |
| No | 42 (95%) | 38 (86%) | 37 (95%) | 36 (92%) |
| Cardiovascular disease | ||||
| Yes | 20 (45%) | 14 (32%) | 10 (26%) | 9 (23%) |
| No | 24 (55%) | 30 (68%) | 29 (74%) | 30 (77%) |
| Ethnicity | ||||
| White | 43 (98%) | 42 (95%) | 36 (92%) | 39 (100%) |
| Black | 0 | 0 | 0 | 0 |
| Asian | 1 (2%) | 2 (5%) | 2 (5%) | 0 |
| Mixed | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 1 (3%) | 0 |
| Not given | 0 | 0 | 0 | 0 |
Data are median (IQR) or n (%).